Welcome to Drugs in Context

Drugs in Context is a member of the Directory of Open Access Journals, listed on PubMed with all articles free-to-view/download immediately on PubMed Central

About

Drugs in Context publishes high-quality, peer-reviewed articles covering the latest evidence and innovations in drug treatment across all therapeutic areas. We focus on original research papers and topical review articles; other article types are considered.

Journal metrics

Scopus CiteScore 2021: 8.1; SCImago Journal Rank 2021: 1.130; Source Normalized Impact per Paper: 1.915; Ranked 52 of 826 (93rd percentile) in General Medicine journals and 55 of 303 (82nd percentile) in Pharmacology journals.

Article types

We publish original research papers and topical review articles. Other article types, including systematic reviews and meta-analyses, editorials, case reports, conference reports and Letters to the Editor, are also considered.

Peer review

All manuscripts undergo single-blind external peer review with comments from at least two reviewers. A first editorial decision is expected within 4 weeks of submission and online publication within 4 weeks after acceptance.

Submit your manuscript

Check the SUBMISSION page for full instructions. Submit your manuscript via Manuscript Manager.

Editorial Board

Drugs in Context is led by a team of Senior Editors supported by an extensive Editorial Board with expertise spanning all areas of modern medicine and pharmacotherapy.

Publishing Process & Peer Review

Drugs in Context is an Open Access journal, with articles freely accessible online for all readers. Articles are assessed for suitability upon submission or pre-submission and then sent for external peer review. There is no charge for submitting a manuscript for consideration.

Instructions for Authors

Publication in Drugs in Context is facilitated by our dedicated and responsive Editorial team. We offer simple and straightforward publication following best practices. For detailed submission guidelines, how to prepare your manuscript, timelines and charges, please read this section.

Latest Articles

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Biagio Ricciuti, Alessia Mira, Elisa Andrini, Pietro Scaparone, Sandra Vietti Michelina, Federica Pecci, Luca Cantini, Andrea De Giglio, Giuseppe Lamberti, Chiara Ambrogio, Giulio Metro

The authors review the current treatment landscape for patients with advanced non-small-cell lung cancers harbouring a KRAS G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options.

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.